Registrant’s
telephone number, including area code: (817)-529-2300
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Securities
registered pursuant Section 12(b) of the Act: None
Title
of each class
Trading
Symbol(s)
Name
of each exchange on which registered
--
--
--
Indicate
by check mark whether the registrant is an emerging growth company
as defined in in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this
chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
checkmark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Effective October12, 2020, the Board of Directors (the “Board”) of
Sanara MedTech Inc. (the “Company”) appointed Robert A.
DeSutter to the Company’s Board. Mr. DeSutter is a managing
director in Piper Sandler healthcare investment banking. He has
twenty-seven years of experience in healthcare investment banking
at Piper Sandler and served as global group head from 2003 to 2018.
Over that period, the group became one of the leading and most
respected healthcare investment banking practices. Mr. DeSutter is
a graduate of the University of Minnesota and the University of
Virginia's Darden Graduate School of Business. The Company believes
the addition of Mr. DeSutter to its Board represents an important
step in the Company’s growth plans.
The
Company anticipates that Mr. DeSutter will be appointed to the
audit committee. If the Board elects to form a nominating and
corporate governance committee, the Company anticipates that Mr.
DeSutter would be appointed to that committee.
Item
7.01 Regulation FD Disclosure.
On
October 15, 2020, the Company issued a press release announcing the
appointment of Mr. DeSutter to the Board. A copy of the press
release is attached as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
by reference herein.
The
information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be deemed
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities under that Section. Further, the information in
Item 7.01 of this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be incorporated by reference into the
filings of the Company under the Securities Act of 1933, as
amended. Item 7.01 of this Current Report on Form 8-K will not be
deemed an admission as to the materiality of any information in
this Current Report on Form 8-K that is required to be disclosed
solely by Regulation FD.
Press
Release issued October 15, 2020 (furnished pursuant to Item
7.01).
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Company
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
